India, March 26 -- Shares of OSR Holdings, Inc. (OSRH) surged over 125% on Wednesday morning driven by results from a Phase 2a Trial of VXM01 vaccine and EMD Serono's Avelumab combination therapy in Glioblastoma.
OSRH is currently trading at $3.6000, up $2.0000 or 125.0078%, on a huge volume of 48 million shares, above average volume of 1.2 million, on the Nasdaq. The stock opened its trading at $4.1501 after closing Tuesday at $1.6000. The stock has traded between $1.3000 and $13.4000 in the past 52-week period.
The results were announced by Vaximm AG, a subsidiary of OSR Holdings. Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further i...